Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

ANTITHROMBOTIC THERAPY IN 2018

A farewell to aspirin in primary prevention?

More than 150 years after acetylsalicylic acid was synthesized by French chemist Charles Frédéric Gerhardt, aspirin is still one of the most prescribed medications worldwide. In 2018, several trials have suggested that the role of aspirin in the contemporary era might be less pre-eminent than in previous decades.

Key advances

  • The risk–benefit ratio of aspirin does not seem to be beneficial in the primary prevention of cardiovascular disease, including in high-risk patients such as those with diabetes mellitus and elderly individuals1,2,7.

  • Aspirin always increases the risk of bleeding when prescribed either alone or in combination with other antiplatelet or anticoagulant drugs1,2,4,5,7.

  • Aspirin can be removed from the antithrombotic regimen immediately after percutaneous coronary intervention in patients receiving anticoagulant therapy plus clopidogrel; safety is then improved and efficacy preserved5.

  • P2Y12 antagonist monotherapy after coronary stenting is currently being tested to replace dual antiplatelet therapy; although statistically neutral, the first study on P2Y12 antagonist monotherapy to be published, the GLOBAL LEADERS trial, showed promising results6.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Aspirin in different CVD prevention situations.

References

  1. 1.

    Gaziano, J. M. et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet 392, 1036–1046 (2018).

    CAS  Article  Google Scholar 

  2. 2.

    The ASCEND Study Collaborative Group. Effects of aspirin for primary prevention in persons with diabetes mellitus. N. Engl. J. Med. 379, 1529–1539 (2018).

    Article  Google Scholar 

  3. 3.

    Antithrombotic Trialists’ Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373, 1849–1860 (2009).

    Article  Google Scholar 

  4. 4.

    Ridker, P. M. Should aspirin be used for primary prevention in the post-statin era? N. Engl. J. Med. 379, 1572–1574 (2018).

    Article  Google Scholar 

  5. 5.

    Golwala, H. B. et al. Safety and efficacy of dual versus triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. Eur. Heart J. 39, 1726–1735a (2018).

    Article  Google Scholar 

  6. 6.

    Vranckx, P. et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months versus aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet 392, 940–949 (2018).

    CAS  Article  Google Scholar 

  7. 7.

    McNeil, J. J. et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N. Engl. J. Med. 379, 1509–1518 (2018).

    CAS  Article  Google Scholar 

  8. 8.

    Bonaca, M. P. et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N. Engl. J. Med. 372, 1791–1800 (2015).

    Article  Google Scholar 

  9. 9.

    Eikelboom, J. W. et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N. Engl. J. Med. 377, 1319–1330 (2017).

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Gilles Montalescot.

Ethics declarations

Competing interests

G.M. has received research grants from Abbott, Actelion, Amgen, AstraZeneca, Bayer, Beth Israel Deaconess Medical Center, Boehringer Ingelheim, Boston Scientific, Brigham and Women’s Hospital, Bristol-Myers Squibb, Cardiovascular Research Foundation, Daiichi-Sankyo, Elsevier, Europa, Fédération Française de Cardiologie, ICAN, Idorsia, Journal of the American College of Cardiology, Lead-Up, Lilly, Medtronic, Menarini, MSD, Novo Nordisk, Pfizer, Sanofi, Servier, The Mount Sinai School of Medicine, TIMI Study Group and WebMD.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Montalescot, G. A farewell to aspirin in primary prevention?. Nat Rev Cardiol 16, 76–77 (2019). https://doi.org/10.1038/s41569-018-0148-z

Download citation

Further reading

Search

Quick links